The safety and efficacy of investigational products or uses has not been determined and is not approved by the United States Food and Drug Administration (FDA)

GM-CSF and Sargramostim Publications


Oncology

Immune Oncology

Neuroblastoma

Hematology

Immunomodulation

Pulmonary Alveolar Proteinosis

  • Inhaled GM-CSF for pulmonary alveolar proteinosis
    Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K. N Engl J Med. 2019;381(10):923-932. doi:10.1056/NEJMoa1816216

Infection

Immune Dysfunction

Immunosuppression in Sepsis and Critical Care

Sepsis and Septic Shock

Influenza, Pneumonia, and Acute Respiratory Distress Syndrome (ARDS)

COVID-19

Hematopoietic Acute Radiation Syndrome

  • The lethality of radiation-induced sepsis and associated immune dysregulation highlight the importance of restoring lymphocyte and monocyte levels and function after total body irradiation (TBI)
    McManus J, Jackson IL, Dainak NP. [abstract]
    Poster presented at Radiation Research Society Annual Meeting; September 15-18, 2024; Tucson, Arizona.
  • Expanding the utility of Leukine®, an FDA-approved treatment for hematopoietic acute radiation syndrome (H-ARS), as a medical countermeasure (MCM) to counter higher priority and emerging chemical, biological and radio-nuclear threats
    Joshi I, Eisele MD, Adney D, McManus J. [abstract]
    Presentation presented at Chemical and Biological Defense Science & Technology Conference (CBD S&T) Conference; December 9, 2022; San Francisco, CA.

Sulfur Mustard Exposure

  • Expanding the use of an FDA-approved host-directed therapy for known and unknown threats: treating pancytopenia and immune dysregulation due to acute radiation or sulfur mustard (HD) exposure with Leukine® [sargramostim/recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)]
    Doyle-Eisele M, Hartsough M, Jackson IL, Joshi I, Ahuja S, McManus J. [abstract]
    Poster presented at Chemical and Biological Defense Science & Technology (CBD S&T) Conference; December 2-5, 2024; Fort Lauderdale, Fl.
  • Developing a host-directed therapy for multiple threats and complex combined injuries: treating pancytopenia and resulting infection, sepsis, and hemorrhage due to acute radiation or sulfur mustard exposure plus trauma with Leukine®
    Joshi I, Adney D, Doyle-Eisele M, Jackson IL, Roychowdhury D, Ahuja S, McManus J. [abstract]
    Presentation presented at Military Health System Research Symposium; August 14-17, 2023; Kissimmee, Fl.

Precision Medicine in Sepsis and Critical Care

  • T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
    Venet F, Gossez M, Bidar F, Bodinier M, Coudereau R, Lukaszewicz AC, Tardiveau C, Brengel-Pesce K, Cheynet V, Cazalis MA, Pescarmona R, Garnier L, Ortillon M, Buisson M, Bouscambert-Duchamp M, Morfin-Sherpa F, Casalegno JS, Conti F, Rimmelé T, Argaud L, Cour M, Saadatian-Elahi M, Henaff L, Vanhems P, Monneret G; RICO study group. EBioMedicine. 2022;78:103967. doi: 10.1016/j.ebiom.2022.103967

Central Nervous System

Alzheimer’s Disease

Parkinson’s Disease

Note: Not all clinical trials and publications of sargramostim are listed.

The safety and efficacy of investigational products or uses has not been determined and is not approved by the United States Food and Drug Administration (FDA)